TherapeuticsMD, Inc.
TXMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.02 | -0.01 | 0.03 |
| FCF Yield | 7.38% | 0.00% | -8.78% | -103.19% |
| EV / EBITDA | -4.03 | -3.36 | 1.78 | -3.90 |
| Quality | ||||
| ROIC | -13.31% | -22.35% | 2.65% | -74.92% |
| Gross Margin | 100.00% | 100.00% | 98.00% | 45.51% |
| Cash Conversion Ratio | -0.32 | 6.25 | -3.80 | 1.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.69% | -20.31% | 2.55% | -62.72% |
| Free Cash Flow Growth | 0.00% | 100.00% | 97.00% | 8.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.71 | -0.45 | -2.47 | -1.87 |
| Interest Coverage | -501.05 | 0.00 | 0.00 | -2.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.18 |
| Cash Conversion Cycle | 738.29 | 866.24 | -564.87 | 6,238.04 |